<DOC>
	<DOCNO>NCT00749138</DOCNO>
	<brief_summary>A short 14 day phase 1 study examine 6 monotherapy dos oral tamoxifen safety chronic HCV patient fail standard treatment peginterferon ribavirin .</brief_summary>
	<brief_title>Fourteen Day Safety Low-Dose Tamoxifen Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy</brief_title>
	<detailed_description>Six different dosage tamoxifen give 14 day safety viral load measure .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . HCV RNA positive . 2. failed standard therapy 1 . Cirrhosis biopsy 2 . Severe medical psychiatric condition would make evaluation difficult 3 . Tamoxifen pregnancy category D drug pregnant woman must exclude . 4 . Patients coumadin use drug interaction . 5 . Active use alcohol illegal substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>hepatitis C , tamoxifen</keyword>
</DOC>